<DOC>
	<DOCNO>NCT03086356</DOCNO>
	<brief_summary>The primary objective trial investigate pharmacokinetics pharmacodynamics idarucizumab Chinese healthy male female subject follow intravenous administration idarucizumab follow idarucizumab 15 minute interval administer close steady state dabigatran . Another objective trial explore effect idarucizumab PK ( pharmacokinetic ( ) ) PD ( pharmacodynamic ) parameter dabigatran .</brief_summary>
	<brief_title>Study Evaluate Safety , Pharmacokinetics Pharmacodynamics Idarucizumab ( BI 655075 ) Administered Alone With Dabigatran Etexilate Chinese Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : Age &gt; = 18 Age &lt; = 45 year screen Healthy male female base upon complete medical history , include vital sign ( Blood Pressure , Pulse Rate , Body Temperature ) , 12lead Electrocardiogram clinical laboratory test . Women childbearing potential must ready able use highly effective method birth control per International Committee Harmonisation M3 ( R2 ) result low failure rate le 1 % per year use consistently correctly . A list contraception method meet criterion provide patient information . Body weight &gt; =50 kg body mass index range &gt; =19.0 &lt; 24.0 kg/m2 Visit 1 . Signed date write informed consent accordance Good Clinical Practice local legislation prior admission trial . Exclusion criterion : Any find medical examination ( include Blood Pressure , Pulse Rate , Body Temperature Electrocardiogram ) deviate normal judge clinically relevant investigator Any evidence clinically relevant concomitant disease accord investigator 's clinical judgement Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract could interfere kinetics trial medication ( except appendectomy ) Diseases central nervous system ( include limit kind seizuresor stroke ) , relevant neurological psychiatric disorder History relevant orthostatic hypotension , faint spell blackout . Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) immune system disease Intake drug long halflife ( &gt; 24 hour ) within least 30 day less 10 halflives respective drug prior first trial drug administration Within 10 day prior administration trial medication , use drug might reasonably influence result trial might prolong QT/QTc ( correct QT ) interval . Participation another trial investigational drug administration within 60 day prior first trial drug administration Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke hospitalization Alcohol abuse ( consumption 20 g per day : e.g. , 1 middlesized bottle beer , 1 gou [ equivalent 180 mL ] sake ) ) Drug abuse positive drug screen Blood donation ( 400 mL whole blood donation within 12 week , 200 mL whole blood donation blood component donation within 4 week ) prior first trial drug administration Intention perform excessive physical activity within one week prior first trial drug administration trial Any laboratory value outside reference range clinical relevance accord investigator 's clinical judgement Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTcF interval &gt; 450 m ) A history additional risk factor TdP ( torsades de point ) ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) Positive HIV ( human immunodeficiency virus ) test result screen examination Positive test Hepatitis B Antigen and/or positive Hepatitis C antibody test result screen examination Subjects consider unsuitable inclusion investigator , e.g . unable understand comply trial requirement , condition opinion investigator would allow safe participation trial . Subjects agree minimize risk female partner become pregnant first dose day 12 week trial completion . Acceptable method contraception comprise barrier contraception medically accept contraceptive method female ( intrauterine device spermicide . hormonal contraceptive since least 8 week ) History evidence blood dyscrasia , haemorrhagic diathesis , severe thrombocytopenia , cerebrovascular haemorrhage , bleed tendency associate active ulceration overt bleed gastrointestinal , respiratory genitourinary tract disease condition haemorrhagic tendency ( e.g . cerebral aneurysm , dissect aorta , CNS trauma , retinopathy , nephrolithiasis ) Abnormal value PT ( prothrombin time ) , aPTT ( activate partial thromboplastin time ) thrombocytes consider investigator one coinvestigators clinically relevant Creatinine estimate glomerular filtration rate ( GFR ) outside normal range Evidence proteinuria Women pregnant , nursing , plan become pregnant trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>